Open Journal of Blood Diseases

Volume 7, Issue 3 (September 2017)

ISSN Print: 2164-3180   ISSN Online: 2164-3199

Google-based Impact Factor: 0.62  Citations  

Drug-Induced Hemolytic Anemia: A Fatal Complication Further Under-Recognized in Sickle Cell Disease

HTML  XML Download Download as PDF (Size: 474KB)  PP. 79-85  
DOI: 10.4236/ojbd.2017.73008    855 Downloads   1,742 Views  

ABSTRACT

Drug-induced immune hemolytic anemia (DIIHA) is commonly attributed to cephalosporins. Ceftriaxone is the most frequently administered cephalosporin in patients with sickle cell disease. We present a pediatric patient with severe DIIHA (hemoglobin < 2 g/dl) who survived. Since DIIHA often goes undiagnosed until late in the course, vigilance of DIIHA minimizes unnecessary diagnostic tests and therapies. DIIHA likely remains under-recognized in all patient subpopulations due to its rarity and overlapping presentations with other conditions. Distinction between exacerbation of chronic hemolysis and new onset of acute hemolysis poses a unique challenge in patients with sickle cell disease. A thorough analysis is warranted to better identify factors within the pediatric sickle cell population that may increase the predisposition for DIIHA, particularly due to ceftriaxone.

Share and Cite:

Khurana, M. and Raj, S. (2017) Drug-Induced Hemolytic Anemia: A Fatal Complication Further Under-Recognized in Sickle Cell Disease. Open Journal of Blood Diseases, 7, 79-85. doi: 10.4236/ojbd.2017.73008.

Cited by

No relevant information.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.